- Home
- ELMD vs CRGX Comparison
ELMD vs CRGX Comparison
Compare ELMD & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELMD
- CRGX
- Stock Information
- Founded
- ELMD 1992
- CRGX 2021
- Country
- ELMD United States
- CRGX United States
- Employees
- ELMD N/A
- CRGX N/A
- Industry
- ELMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CRGX
- Sector
- ELMD Health Care
- CRGX
- Exchange
- ELMD Nasdaq
- CRGX Nasdaq
- Market Cap
- ELMD 190.6M
- CRGX 190.0M
- IPO Year
- ELMD 2010
- CRGX 2023
- Fundamental
- Price
- ELMD $20.20
- CRGX $4.25
- Analyst Decision
- ELMD Strong Buy
- CRGX Hold
- Analyst Count
- ELMD 1
- CRGX 7
- Target Price
- ELMD $38.00
- CRGX $4.67
- AVG Volume (30 Days)
- ELMD 78.3K
- CRGX 569.8K
- Earning Date
- ELMD 05-13-2025
- CRGX 05-08-2025
- Dividend Yield
- ELMD N/A
- CRGX N/A
- EPS Growth
- ELMD 60.99
- CRGX N/A
- EPS
- ELMD 0.79
- CRGX N/A
- Revenue
- ELMD $61,439,000.00
- CRGX N/A
- Revenue This Year
- ELMD $17.91
- CRGX $58.18
- Revenue Next Year
- ELMD $11.70
- CRGX N/A
- P/E Ratio
- ELMD $25.60
- CRGX N/A
- Revenue Growth
- ELMD 14.85
- CRGX N/A
- 52 Week Low
- ELMD $13.74
- CRGX $3.00
- 52 Week High
- ELMD $35.56
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- ELMD 40.14
- CRGX 53.57
- Support Level
- ELMD $19.52
- CRGX $3.78
- Resistance Level
- ELMD $20.60
- CRGX $4.27
- Average True Range (ATR)
- ELMD 1.12
- CRGX 0.18
- MACD
- ELMD -0.04
- CRGX 0.03
- Stochastic Oscillator
- ELMD 33.41
- CRGX 88.79
About ELMD Electromed Inc.
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.